newsfilter
← Latest News
Earnings Call Transcripts·

Septerna - 1781718 - SEPTERNA INC

  • Financial Performance:

    • No specific revenue, earnings, cash flow, debt, or margin figures disclosed in this presentation transcript, as the company (Septuna) is a pre-commercial biotech focused on clinical development.
    • A prior partnership with Novo was mentioned as active, with a development candidate selected in Q3 2025, implying ongoing funding/collaboration activity.
  • Guidance and Future Outlook:

    • SCP-479 (Hyperparathyroidism): Phase 1 trial readout anticipated in Q1 2027; Phase 2 trial targeting H2 2026 enrollment pending completion of chronic toxicology studies.
    • SCP-204 (Graves' Disease/Thyroid Eye Disease): Phase 1 trial initiation scheduled for Q1 2027; healthy volunteer data expected by end of 2027.
    • SCP-631 (Mast Cell): Currently in the signal-finding phase; strategy focuses on smaller studies to identify promising indications (e.g., migraine, interstitial cystitis) before larger Phase 2 trials.
    • Novo Collaboration: Five concurrent targets; first development candidate selected and moving forward.
  • Business Segments and Product Lines:

    • SCP-479 (PTH1R Agonist): Oral small molecule for hyperparathyroidism (post-surgical); utilizes "Native Complex Platform" to mimic peptide function at two distinct binding pockets; preclinical half-life 3–4 days.
    • SCP-204 (TSHR Antagonist): Oral small molecule for Graves' disease and thyroid eye disease; demonstrates ability to normalize or suppress thyroid hormones in preclinical models; selective against FSH/LH receptors.
    • SCP-631 (MRGPRX2 Antagonist): Negative allosteric modulator for mast cell-mediated diseases; completed Phase 1; high receptor occupancy (~99%) with slow off-rate.
    • Osteoporosis Program: Second PTH receptor agonist utilizing a short-acting compound profile to promote bone formation.
  • Market and Competitive Landscape:

    • Hyperparathyroidism: Addresses 70,000–80,000 US patients; current standard of care is daily injections (Voryphath) or calcium/vitamin D supplements; unmet need for oral alternatives to improve adherence.
    • Differentiation: SCP-479 is the only oral PTH replacement in development; distinct mechanism from competitor Encallerate (Calcium-sensing receptor agonist), which requires intact parathyroid tissue and is unsuitable for the primary post-surgical patient population.
    • Graves' Disease: Significant unmet need with high relapse rates on antithyroid drugs; few options for thyroid eye disease; SCP-204 targets the root autoantibody mechanism (TSH receptor).
  • Risks and Challenges:

    • Clinical Translation: Reliance on healthy volunteer data as a proof-of-concept for patient efficacy in endocrine feedback loops.
    • Development History: Historical difficulty in developing oral small molecules for GPCRs; previous Mast Cell (X2) programs in Chronic Spontaneous Urticaria (CSU) failed, necessitating a strategic pivot.
    • Toxicology: Preclinical models show "exaggerated on-target pharmacology" (hypothyroidism in SCP-204 models), requiring careful dose titration in humans.
  • Management Commentary and Tone:

    • Confidence: Management expressed strong confidence in their platform's ability to solve the "decades-old" challenge of oral GPCR small molecules.
    • Tone: Optimistic yet realistic; emphasized leveraging preclinical data and established biology (e.g., Voryphath success) to de-risk development.
    • Strategic Focus: Pivot to "signal-finding" studies for the mast cell program rather than large-scale Phase 2s; commitment to completing chronic toxicology early to facilitate open-label extensions for patient retention.
  • Analyst Questions and Answers:

    • Q: Is healthy volunteer data sufficient for hyperparathyroidism proof-of-concept? A: Yes; fundamental receptor biology is identical in healthy volunteers and patients, and all successful compounds in healthy volunteers have succeeded in patients.
    • Q: How does SCP-479 compare to competitor Encallerate? A: Mechanistically distinct; Encallerate targets the calcium-sensing receptor and requires intact PTH production, making it unsuitable for post-surgical patients where Septuna is focused.
    • Q: What is the strategy for the Mast Cell (SCP-631) program after CSU failure? A: Pivoting to smaller, signal-finding studies in indications with strong emerging data (migraine, interstitial cystitis, asthma) to validate efficacy before committing to large trials.
    • Q: What dosing strategy is anticipated for hyperparathyroidism? A: Titration protocol similar to injectable peptides, starting low and increasing while decreasing calcium/vitamin D supplements; goal is once-daily oral dosing.
  • Other Key Points:

    • Platform Capabilities: The "Native Complex Platform" successfully identified two distinct binding pockets for the PTH1R receptor, a feat previous attempts by major pharma had not achieved.
    • Dose Optionality (SCP-204): Preclinical data suggests dose-dependent outcomes, with potential for both normalization of thyroid function and full suppression (hypothyroidism), offering flexibility in treatment.
    • Half-Life Optimization: SCP-479 achieved a half-life at the high end of projections (3–4 days), enabling stable calcium control with once-daily dosing.
Company
SEPTERNA INC
Keywords
SEPTERNA INC